<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199524</article-id><article-id pub-id-type="doi">10.1101/2024.10.15.618397</article-id><article-id pub-id-type="archive">PPR926300</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>How do gepotidacin and zoliflodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 1. Experimental definition of metal binding sites</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>Harry</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nicholls</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Warren</surname><given-names>Anna J.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ward</surname><given-names>Simon E.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Gwyndaf</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Long</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Murshudov</surname><given-names>Garib N.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Duman</surname><given-names>Ramona</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bax</surname><given-names>Benjamin D.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Medicines Discovery Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03kk7td41</institution-id><institution>Cardiff University</institution></institution-wrap></aff><aff id="A2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05etxs293</institution-id><institution>Diamond Light Source</institution></institution-wrap>, <addr-line>Harwell Campus</addr-line>, <city>Didcot, Oxfordshire</city>. <postal-code>OX11 0DE</postal-code>, <country country="GB">UK</country></aff><aff id="A3"><label>3</label>Scientific Computing Department, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/057g20z61</institution-id><institution>UKRI Science and Technology Facilities Council</institution></institution-wrap>, <addr-line>Harwell Campus</addr-line>, <city>Didcot, Oxfordshire</city>. <postal-code>OX11 0DE</postal-code>, <country country="GB">UK</country></aff><aff id="A4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00tw3jy02</institution-id><institution>MRC Laboratory of Molecular Biology</institution></institution-wrap>, <city>Cambridge</city></aff><author-notes><corresp id="CR1">
<label>*</label>Correspondence: <email>BaxB@cardiff.ac.uk</email>;</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>19</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>17</day><month>10</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">One of the challenges for experimental structural biology in the 21st century is to see chemical reactions happen. <italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic>) DNA gyrase is a type IIA topoisomerase that can create temporary double-stranded DNA breaks to regulate DNA topology. Drugs, such as gepotidacin, zoliflodacin and the quinolone moxifloxacin, can stabilize these normally transient DNA-strand breaks and kill bacteria. Crystal structures of uncleaved DNA with a gepotidacin precursor (2.1Å GSK2999423) or with doubly cleaved DNA and zoliflodacin (or with its progenitor QPT-1) have been solved in the same P6<sub>1</sub> space-group (a=b≈93Å, c≈412Å). This suggests it may be possible to observe the two DNA-cleavage steps (and two DNA-religation steps) in this P6<sub>1</sub> space-group. Here a 2.58Å anomalous manganese dataset in this crystal form is solved, and four previous crystal structures (1.98Å, 2.1Å, 2.5Å and 2.65Å) in this crystal form are re-refined to clarify crystal contacts. The structures clearly suggest a single moving metal mechanism - presented in an accompanying (2nd) paper. A previously published 2.98Å structure of a yeast topoisomerase II, which has static disorder around a crystallographic twofold axis, was published as containing two metals at one active site. Re-refined coordinates of this 2.98Å yeast structure are consistent with other type IIA topoisomerase structures in only having one metal ion at each of the two different active sites.</p></abstract><kwd-group><kwd>Novel bacterial topoisomerase inhibitor (NBTI)</kwd><kwd>spirocyclic pyrimidinetrione (SPT)</kwd><kwd>gepotidacim</kwd><kwd>zoliflodacin</kwd><kwd>type IIA topoisomerase</kwd><kwd>DNA-cleavage</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><label>1</label><title>Introduction</title><p id="P2">How the two bacterial type IIA topoisomerases, DNA gyrase and topoisomerase IV, cleave DNA is not merely of academic interest. DNA gyrase and its homolog, topoisomerase IV, are targets of well characterized fluoroquinolone antibiotics (e.g., ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin) which continue to be widely used in clinical practice despite serious safety concerns [<xref ref-type="bibr" rid="R1">1</xref>]. Such compounds, known as topoisomerase poisons, stabilize intermediate DNA-cleavage complexes formed during catalysis that lead to accumulation of DNA double strand breaks and bacterial cell death [<xref ref-type="bibr" rid="R2">2</xref>]. Structural studies explained how common topoisomerase mutations confer clinical resistance to fluoroquinolones [<xref ref-type="bibr" rid="R3">3</xref>]. Recently the first members of two new classes of gyrase-targeting antibiotics, that are not susceptible to these common fluoroquinolone resistance mutations, have successfully completed phase III clinical trials (and could therefore be marketed for clinical use): a spirocyclic pyrimdinetrione (SPT) zoliflodacin [<xref ref-type="bibr" rid="R4">4</xref>], and a 'novel bacterial topoisomerase inhibitor' (NBTI) gepotidacin [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. Zoliflodacin is derived from its progenitor QPT-1 (for quinoline pyrimidine trione [<xref ref-type="bibr" rid="R7">7</xref>]). Zoliflodacin [<xref ref-type="bibr" rid="R8">8</xref>] and QPT-1 [<xref ref-type="bibr" rid="R9">9</xref>] stabilize double-stranded DNA-breaks by sitting in the two, four base-pair separated, DNA-cleavage sites, in a similar manner to quinolones such as moxifloxacin [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>]. NBTIs such as GSK299423 [<xref ref-type="bibr" rid="R11">11</xref>] and gepotidacin [<xref ref-type="bibr" rid="R6">6</xref>] have been observed to bind on the twofold axis of complexes, midway between the two four base-pair staggered DNA-cleavage sites, and have been observed to stabilize single stranded DNA-cleavage complexes [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R11">11</xref>]. The rise of antibacterial resistance in the 21<sup>st</sup> century is a major global healthcare threat; the new NBTI and SPT classes of antibacterial drugs should help with this problem.</p><p id="P3">Antibacterial resistance occurs when bacteria develop mechanisms to survive, grow and multiply in the presence of antibacterial compounds, which are normally capable of killing bacterial cells [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>]. Studies have shown that infection by antimicrobial resistant (AMR) pathogens can lead to severe illnesses and in certain cases, death [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>]. In the United States, the Centre for Disease Control (CDC) estimated the cost of AMR to be $55 billion per year, considering both healthcare costs and productivity loss [<xref ref-type="bibr" rid="R15">15</xref>]. Findings from the European Centre for Disease Control (ECDC) showed that across the three main antimicrobial groups presented (carbapenems, fluoroquinolones and aminoglycosides), the increase in the number of antimicrobial-resistant isolates was greater in 2021 when compared to the averages for 2018 and 2019, at an average increase of +121% across the three antimicrobial groups [<xref ref-type="bibr" rid="R16">16</xref>]. Although resistance to the bacterial topoisomerase targeting fluoroquinolones (ciprofloxacin/levofloxacin/ofloxacin) was only some 5% to &lt; 10% in 2021 in the UK and France, eastern European countries like Poland and Ukraine reported figures of 25% to &lt; 50% [<xref ref-type="bibr" rid="R16">16</xref>] while in Russia and Turkey, fluoroquinolone-resistant <italic>E. coli</italic> was present in ≥ 50% of invasive isolates [<xref ref-type="bibr" rid="R16">16</xref>]. Such high percentages of <italic>E. coli</italic> resistance to these compounds are concerning as the Gram negative <italic>E. coli</italic> is the dominant bacteria responsible for many common human diseases including, but not limited to, urinary tract infection (UTI), enteritis and septicemia [<xref ref-type="bibr" rid="R17">17</xref>]. It is not yet certain if the higher resistance rates seen in some countries are due to the presence of antibiotics in the environment [<xref ref-type="bibr" rid="R18">18</xref>]. The NBTI gepotidacin has successfully passed a phase III clinical trial for urinary tract infection (UTI) [<xref ref-type="bibr" rid="R19">19</xref>], while zoliflodacin [<xref ref-type="bibr" rid="R20">20</xref>] has recently successfully passed a phase III clinical trial for a Gram negative caused infection, gonorrhea [<xref ref-type="bibr" rid="R21">21</xref>]. The balanced dual targeting of both DNA gyrase and Topoisomerase IV by gepotidacin decreases the chance of resistance developing [<xref ref-type="bibr" rid="R22">22</xref>].</p><p id="P4">Enzymes which change the topology of DNA, topoisomerases, are divided into two classes; type I and type II, which introduce single-stranded and double-stranded DNA breaks, respectively, to modify the DNA topology [<xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R25">25</xref>]. DNA gyrase is a bacterial type IIA topoisomerase that can regulate DNA topology by making a temporary double-stranded break in one DNA duplex (in the gate or G-segment, forming a so called cleavage complex) and then passing another DNA duplex (the transport or T-segment) through this break; this is accompanied by large movements in the enzyme [<xref ref-type="bibr" rid="R23">23</xref>] (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S1</xref>). Zoliflodacin [<xref ref-type="bibr" rid="R8">8</xref>] and QPT-1 [<xref ref-type="bibr" rid="R9">9</xref>] are both capable of trapping the four base-pair staggered break in the DNA, as are quinolones.</p><p id="P5">A <italic>S. aureus</italic> DNA gyrase P6<sub>1</sub> crystal system, originally developed to support the development of NBTIs such as gepotidacin [<xref ref-type="bibr" rid="R11">11</xref>], has also now produced crystal structures (see <xref ref-type="table" rid="T1">Table 1</xref>) with both uncleaved DNA [<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R32">32</xref>] and with doubly cleaved DNA complexes stabilized by zoliflodacin [<xref ref-type="bibr" rid="R8">8</xref>] or its progenitor QPT-1 [<xref ref-type="bibr" rid="R9">9</xref>] and an imidazopyrazinone [<xref ref-type="bibr" rid="R33">33</xref>]. Suggesting that, with the proper design of the chemistry [<xref ref-type="bibr" rid="R34">34</xref>] of an experiment, it might be possible to observe DNA-cleavage taking place in these crystals; indeed careful refinement of an imidazopyrazinone complex suggested one DNA-cleavage site contained both cleaved and uncleaved DNA (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S2</xref> in [<xref ref-type="bibr" rid="R33">33</xref>]). Chemistry for pump probe type reactions is being developed [<xref ref-type="bibr" rid="R35">35</xref>], and reactions within crystals normally proceed between 10 and 10,000 times slower than in solution [<xref ref-type="bibr" rid="R36">36</xref>]. It may be possible, with careful design of chemistry, to perform such experiments at a synchrotron [<xref ref-type="bibr" rid="R37">37</xref>] - however the possibility of doing such experiments at an XFEL [<xref ref-type="bibr" rid="R37">37</xref>] should not be ruled out.</p><p id="P6">By the time a paper (submitted in Ocotber 2009 with the title: ''<italic>Structural basis for DNA cleavage by type IIA topoisomerases revealed by a new class of broad spectrum antibacterial</italic>') was published in August 2010 entitled: '<italic>Type IIA topoisomerase inhibition by a new class of antibacterial agents'</italic> [<xref ref-type="bibr" rid="R11">11</xref>]) the first structure showing the existence of the quinolone water-metal ion bridge [<xref ref-type="bibr" rid="R3">3</xref>] had been accepted. To indicate the problems encountered in determining a <italic>S. aureus</italic> gyrase 3.35Å with the quinolone ciprofloxacin structure (pdb code: 2XCT) it was chosen, in 2010, to release coordinates with a clearly incomplete coordination geometry for the quinolone associated metal ions. Corrected coordinates, consistent with subsequently determined better higher resolution quinolone structures [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>], are now available at <ext-link ext-link-type="uri" xlink:href="https://profiles.cardiff.ac.uk/staff/baxb">https://profiles.cardiff.ac.uk/staff/baxb</ext-link> - click on 'research' tab - and scroll down then click on '<underline><styled-content style="color:#954F72">2xct-v2-BA-x.pdb</styled-content></underline>' to download coordinates (the Protein Data Bank did not accept deposition of these corrected coordinates).</p><p id="P7">Also in 2010 a paper purporting to show a '<italic>A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases'</italic> was published in Nature [<xref ref-type="bibr" rid="R42">42</xref>]. The mechanism proposed in this paper was based on a 2.98Å structure in which two metal ions (zinc ions) had been placed in peaks in an electron density map. However, this published structure (pdb code: 3L4K) takes no account of the static disorder around a crystallographic twofold; the two different active sites are modelled with exactly the same metal ion coordination geometry and both active sites ignore normal rules [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>] of metal ion co-ordination geometry. Consequently, this structure has incorrect coordination geometry around these two metal ion sites that does not make chemical sense; it should be corrected [<xref ref-type="bibr" rid="R45">45</xref>]. This yeast structure has now been refined consistently with a single moving metal mechanism [<xref ref-type="bibr" rid="R41">41</xref>] and with reasonable metal ion coordination geometry at each of the two different active sites (coordinates at <ext-link ext-link-type="uri" xlink:href="https://profiles.cardiff.ac.uk/staff/baxb">https://profiles.cardiff.ac.uk/staff/baxb</ext-link> - click on 'research' tab - and scroll down then click on <underline><styled-content style="color:#8B8BFF">RR-3l4k.pdb</styled-content></underline> - RR = re-refined). One of the re-refined structures (see <xref ref-type="table" rid="T1">Table 1</xref>), the 1.98Å <underline><styled-content style="color:#8B8BFF">5iwi-v2-BA-x.pdb</styled-content></underline>, suffers from similar static disorder to the 2.98Å 3lk4 structure.</p><p id="P8">Two of the other re-refined [<xref ref-type="bibr" rid="R46">46</xref>] P6<sub>1</sub> crystal structures, the 2.1Å <underline><styled-content style="color:#8B8BFF">2xcs-v2-BA-x.pdb</styled-content></underline> and the 2.5Å <underline><styled-content style="color:#8B8BFF">5cdm-v2-BA-x.pdb</styled-content></underline>, are used in the accompanying paper on a single metal mechanism. Rerefining these two structures did not significantly alter the coordination geometry at the active sites; however, it did clarify an important role played by a partially occupied manganese ion (C 901) and a BisTris buffer molecule (C 902) at a crystal contact (with one end of the DNA and a histidine residue whose protonation state inversely correlates with the occupancy of the manganese ion).</p><p id="P9">Finally a <italic>S. aureus</italic> DNA gyrase binary (DNA and protein) crystal structure was also determined, based on data collected at an X-ray wavelength of 1.33 Å (E = 6.6 keV, above the Mn K-edge) (see <xref ref-type="sec" rid="S8">Materials and Methods</xref> and [<xref ref-type="bibr" rid="R47">47</xref>] for details). This structure shows that in addition to the fully occupied catalytic metals, whose occupancies were defined by ensuring their temperature factors are comparable to those of the surrounding atoms [<xref ref-type="bibr" rid="R48">48</xref>], additional sites are present with lower occupancies. In addition to the expected crystal contact partially occupied manganese site [<xref ref-type="bibr" rid="R8">8</xref>], density for additional manganese ions was seen near the quinolone water metal ion bridge in this binary complex with nicked DNA. Consequently the corresponding 2.65Å binary structure was also rerefined (<bold><underline><styled-content style="color:#8B8BFF">5cdr-v2-BAx.pdb</styled-content></underline></bold>).</p><p id="P10">In publishing a previous paper on this subject '<italic>DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion'</italic> [<xref ref-type="bibr" rid="R41">41</xref>], the ideas now fully developed in the accompanying paper [Nicholls <italic>et al</italic>., 2024] [<xref ref-type="bibr" rid="R49">49</xref>] were placed in the supplemental. The two biochemists on the paper, Thomas Germe and Tony Maxwell proposed a scheme, described in the main body of that paper (pages 3438-3447) [<xref ref-type="bibr" rid="R41">41</xref>], which seemed to ignore chemistry 'rules' derived from small molecule crystal structures [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>]. The single moving metal mechanism described in the accompanying paper is more probable (see <xref ref-type="sec" rid="S7">discussion</xref>). The mechanism described in [<xref ref-type="bibr" rid="R49">49</xref>] has sensible chemistry.</p></sec><sec id="S2" sec-type="results"><label>2</label><title>Results</title><p id="P11">In this paper our definitions of low (&gt;3 Å), medium-low (2.51-3.0 Å), medium-high (2.01-2.50 Å) and high (2.0Å or better) resolution X-ray crystal structures of type IIA topoisomerases are defined by how easy it is to determine the coordination geometry of a metal ion at that resolution. These resolution definitions are similar to those used in structure guided drug design, where 'unhappy' waters (which can be displaced) need to be clearly distinguished from 'happy' waters - which have 'optimal' contacts [<xref ref-type="bibr" rid="R50">50</xref>]. For parts of structures complicated by static disorder around a twofold axis (often seen with type IIA topoisomerases) the comparatively poor electron density in these regions invokes map interpretability more akin to structures of around 0.5Å worse resolution. While the initial 2.1Å crystal structure of GSK299423 had no ambiguity for the catalytic metal ion coordination sphere (see <xref ref-type="fig" rid="F5">Figure 5</xref> in Bax et al., 2010 [<xref ref-type="bibr" rid="R11">11</xref>]), the compound, GSK299423, sat on the twofold axis of the complex and was effected by static disorder (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure 10</xref> panels b,c and d in Bax et al., 2010 [<xref ref-type="bibr" rid="R11">11</xref>]). This meant that the water structure around GSK299423 was not very clearly defined in the electron density maps; and since individual water molecules can play an important role in ligand recognition [<xref ref-type="bibr" rid="R51">51</xref>] we sought to improve this situation. The major aim at that time was to support chemistry aimed at developing new NBTIs and a better crystal system was sought - by trying to exploit the different crystal packing observed on the two ends of the DNA duplex in the P6<sub>1</sub> crystal system (see <xref ref-type="sec" rid="S5">section 2.3</xref>). After two years of failure in trying to exploit the slight asymmetry in crystal packing in this crystal form, in 2007 this attempt was abandoned when a structure with GSK945237 and a 'nicked' DNA gave a 1.98Å structure suffering from static disorder around the twofold axis of the complex [<xref ref-type="bibr" rid="R26">26</xref>]; the DNA and compound both suffered from static disorder (whereas in the original GSK299423 structure only the compound suffered from static disorder).</p><p id="P12">In this paper the Y and 3' nomenclature for the two observed metal binding sites is used (see <xref ref-type="sec" rid="S8">Materials and Methods</xref> for details). This was the original nomenclature proposed for the two sites in 2009/2010 [<xref ref-type="bibr" rid="R11">11</xref>]. However, the A=3' and B=Y site nomenclature is also used in case the reader is more familiar with this naming system for the two metal sites. Having the same names for the single metal ion (5081) and the water molecules involved in catalysis is also helpful (see [<xref ref-type="bibr" rid="R49">49</xref>] for details).</p><sec id="S3"><label>2.1</label><title>High resolution structures have clearly defined metals at either the 3'(A)-site or Y(B)-site</title><p id="P13"><italic>In vivo</italic> type IIA topoisomerases are believed to use Mg<sup>2+</sup> ions to cleave DNA, however <italic>in vitro</italic> both Mn<sup>2+</sup> and Ca<sup>2+</sup> ions can also be used by the enzymes to cleave DNA. The two single-strand DNA-cleavage events take place one after the other, resulting in a double-strand break with 4 bp 5’ overhangs [<xref ref-type="bibr" rid="R53">53</xref>]. High-resolution structures of type IIA topoisomerases are difficult to obtain, presumably because of the inherent flexibility of the enzyme. However, the <italic>S.aureus</italic> Greek Key deletion construct tends to give better resolution (see <xref ref-type="table" rid="T1">Table 1</xref> - for twenty P6<sub>1</sub> structures published with this construct).</p><p id="P14">Clear structures of the 3' (or A-site) metal and many structures with Y (or B-site metals) have now been published (see <xref ref-type="fig" rid="F1">Figure 1</xref>). The catalytic tyrosine is believed to be in the tyrosinate form when it cleaves the DNA, becoming covalently attached by a 'phosphotyrosine' bond (see <xref ref-type="fig" rid="F1">figure 1</xref> - and [<xref ref-type="bibr" rid="R49">49</xref>] for more details),</p><p id="P15">When the catalytic tyrosine has cleaved the DNA (as in the 5cdm structure shown in <xref ref-type="fig" rid="F1">Fig 1b</xref>) it effectively becomes a phosphotyrosine, and because it was easier to generate crystallographic restraints it was described as a phosphotyrosine residue (YP123 from A or C chain) in the original 5cdm coordinates. However, the phosphate comes from the DNA and so in the re-refined coordinates (<xref ref-type="fig" rid="F1">Figure 1b</xref>) tyrosine C123 is covalently linked to E2009 and similarly tyrosine A123 is covalently bonded to the phosphorous atom of F2009 (see <xref ref-type="sec" rid="S8">Materials and Methods</xref> for details).</p><p id="P16">Although both the 2.1Å GSK299423 structure and the 2.5Å QPT-1 structure are solved in the same P6<sub>1</sub> space-group, with the asymmetric unit chosen to be close to the origin, the structures are not in identical positions (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S2</xref>). In order to see the movement of the catalytic metal B5081 more clearly the superposition of structures as seen in <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S2</xref> panel d is used in <xref ref-type="fig" rid="F2">Figure 2</xref>. The implied mechanism, with reasonable chemistry, is described in [<xref ref-type="bibr" rid="R49">49</xref>] (see <xref ref-type="supplementary-material" rid="SD1">figures S3</xref> and <xref ref-type="supplementary-material" rid="SD1">S4</xref> in this paper for more experimental details).</p></sec><sec id="S4"><label>2.2</label><title>A comparison of the original 3l4k structure interpreted as having the same metal ion coordination geometry independent of the active sites with re-refined coordinates</title><p id="P17">In 2010 a structure was published and deposited in the PDB [<xref ref-type="bibr" rid="R42">42</xref>] (pdb code: 3L4K). This structure [<xref ref-type="bibr" rid="R42">42</xref>] followed some excellent biochemistry from Deweese and Osheroff [<xref ref-type="bibr" rid="R54">54</xref>–<xref ref-type="bibr" rid="R56">56</xref>] which had been interpreted as supporting a two metal mechanism. However, this interpretation [<xref ref-type="bibr" rid="R42">42</xref>] ignored the existence of two active sites in type IIA topoisomerases (see <xref ref-type="supplementary-material" rid="SD1">supplementary discussion</xref> in [<xref ref-type="bibr" rid="R11">11</xref>]). Although the deposited coordinates for 3L4K [<xref ref-type="bibr" rid="R42">42</xref>] clearly contain two different active sites, they contain identical metal ions at each active site (see <xref ref-type="fig" rid="F3">figure 3</xref> panels a and b). The coordinates clearly imply that, despite having two different active sites in the coordinates, the authors believe this makes no difference to the metal ion coordination geometry. Because 3L4K sits on a crystallographic twofold axis, the observed 2.98Å electron density is effectively a convolution of two structures superposed, related by the crystallographic twofold axis. This makes refinement and interpretation of the electron density more challenging, and more ambiguous than would be the case for an otherwise typical 2.98Å X-ray crystal structure not suffering from such static disorder. Deconvoluted coordinates of the two superposed structures are provided (<underline><styled-content style="color:#8B8BFF">3lk4-c1a.pdb</styled-content></underline> and <underline><styled-content style="color:#8B8BFF">3lk4-c1b.pdb</styled-content></underline>) to clarify the chemistry. In any one yeast dimer only one of these structures exists, but the crystal is composed of many such structures in random orientations about the twofold axis of the dimer, so the observed electron density is an average. The re-refined coordinates for 3L4K are consistent with a 3'(A)-site (<xref ref-type="fig" rid="F3">Figure 3</xref> panel c) in the presence of the scissile phosphate and a Y(B)-site metal in the absence of the scissile phosphate (<xref ref-type="fig" rid="F3">Figure 3</xref> panel d). While the total number of electrons is similar in the two structures (3l4k and re-refined 3l4k - <underline><styled-content style="color:#8B8BFF">RR-3l4k.pdb</styled-content></underline> for which we also provide deconvoluted structures: <underline><styled-content style="color:#8B8BFF">RR-3l4kc1a.pdb</styled-content></underline> and <underline><styled-content style="color:#8B8BFF">RR-3l4k-c1b.pdb</styled-content></underline>), the temperature factors for the two fully occupied zincs in the originally deposited coordinates (<xref ref-type="fig" rid="F3">Figure 3</xref>, panel a and b) are much higher (129 and 138) than those of surrounding atoms; while in the re-refined coordinates the temperature factors (67 and 72) are similar to those of the surrounding atoms [<xref ref-type="bibr" rid="R48">48</xref>]. The original models lack waters and have very unusual coordination spheres (<xref ref-type="fig" rid="F3">Figure 3</xref>, panel a and b). The similarity of the re-refined coordinates to those of 5iwi is noted.</p></sec><sec id="S5"><label>2.3</label><title>Re-refined P6<sub>1</sub> S.aureus structures suggest a manganese ion and BisTris mediate an important crystal contact</title><p id="P18">In order to clarify the crystal contacts in the P6<sub>1</sub> crystal form we re-refined some crystal structures. This followed on from the determination of 8bp2 [<xref ref-type="bibr" rid="R8">8</xref>], a structure with zoliflodacin, which was unusual in being crystallised at a high pH; it was crystallised by microbatch under oil from equal volumes of protein in 342.9 mM HEPES pH 7.2 and precipitate which contained 90 mM Bis-Tris pH 6.3. Usually the protein comes in 20mM HEPES. In the 8bp2 a crystal contact manganese ion (named Mn C901) was modelled at full occupancy coordinated by His C390 (see <xref ref-type="sec" rid="S8">Materials and Methods</xref> for a description of the standard BA-x naming convention used in <italic>S. aureus</italic> DNA gyrase crystal structures). This suggested to us that the variable density seen at this crystal contact might inversly correlate with the protonation state of the histidine C390 side-chain. The re-refined structures seem to confirm this (see <xref ref-type="table" rid="T2">Table 2</xref>), with a higher occupancy for the pH 6.5 structure (<underline><styled-content style="color:#8B8BFF">2xcs-v2-BA-x.pdb</styled-content></underline>) than for the pH 6.2 structures. The 5iwi structure suffers from static disorder around the non-crystallographic twofold axis of the complex, in a similar manner to 3l4k. When the 5iwi structure was initially solved in 2007, with one strand with the scissile phosphate in place and the other strand with an artificial nick in the DNA, attempts at getting asymmetric DNA to crystallize in a single orientation in this P6<sub>1</sub> cell were abandoned [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>].</p></sec><sec id="S6"><label>2.4</label><title>An anomalous dataset confirmed catalytic metal and crystal contact manganese ions, but unexpectedly showed additional manganese density near serine 84</title><p id="P19">The structure (PDB code: 9fz6) was solved from anomalous data collected on beamline I23 [<xref ref-type="bibr" rid="R47">47</xref>] at Diamond Light Source (DLS) using 5cdr as the starting model. The structure showed large anomalous peaks (see <xref ref-type="table" rid="T3">Table 3</xref>) at the two catalytic sites as well as the Mn-coordinated BisTris at a P6<sub>1</sub> crystal contact (see <xref ref-type="table" rid="T3">Table 3</xref> - see <xref ref-type="fig" rid="F4">Figure 4</xref>) and unexpectedly it also showed a new Mn<sup>2+</sup> binding site close to both the free 5' phosphates of the 12p DNA on both strands in this binary complex and close to the side-chain hydroxyl of Ser A84 (or Ser C84). In standard BA-x nomenclature we named this site as E or F/1999 (<xref ref-type="table" rid="T3">Table 3</xref>). An iterative refinement strategy was implemented to estimate Mn<sup>2+</sup> site occupancies, in which the correlation between the Mn<sup>2+</sup> B-factors and the B-factors of coordinating residues was optimized [<xref ref-type="bibr" rid="R48">48</xref>].</p><p id="P20">Electron density at the crystal contact was modelled with a BisTris molecule, consistently as seen previously in 8BP2 [<xref ref-type="bibr" rid="R8">8</xref>] and with other structures (see <xref ref-type="table" rid="T2">Table 2</xref>). These anomalous data give further evidence that the BisTris is required for the formation of P6<sub>1</sub> DNA gyrase/DNA crystals (see <xref ref-type="supplementary-material" rid="SD1">Figure S5</xref> - for an initial wrong attempt - in 2xcs - to model this density). In our experience this P6<sub>1</sub> crystal form tends to grow as two crystals joined by a merohedral twin plane; the anomalous data were collected from two such crystals; therefore the crystal structure is modelled as a near perfect twin. Data were collected at two wavelengths (see <xref ref-type="sec" rid="S8">Materials and Methods</xref>) as seen in <xref ref-type="fig" rid="F5">Figure 5</xref>.</p></sec></sec><sec id="S7" sec-type="discussion"><label>3</label><title>Discussion</title><p id="P21">The <italic>S.aureus</italic> DNA gyrase Greek Key deletion construct, which was originally made to support the development of the NBTI gepotidacin [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R11">11</xref>], tends to crystallise in the P6<sub>1</sub> space-group [<xref ref-type="bibr" rid="R41">41</xref>], and crystals in this space-group have also resulted in structural models for QPT-1 [<xref ref-type="bibr" rid="R9">9</xref>] and zoliflodacin [<xref ref-type="bibr" rid="R8">8</xref>]. Original crystallization screening experiments in 2005 suggested that crystallization only occurs in the presence of BisTris buffer. Because the protein is purified in the presence of 5mM MnCl2 it was proposed in 2023 [<xref ref-type="bibr" rid="R8">8</xref>] that observed electron density on one end of the DNA corresponds to a Mn<sup>2+</sup> ion sitting on His C390 coordinated by BisTris (see <xref ref-type="fig" rid="F4">Figure 4</xref>). With decreasing pH there is less electron density; this histidine C390 side-chain presumably becomes protonated (see [<xref ref-type="bibr" rid="R31">31</xref>] for crystals at pH 5.5 - lacking any Mn<sup>2+</sup> electron density on His C390). However, in our experience this P6<sub>1</sub> crystal form tends to grow, like back-to-back small pencils, from a merohedral twin plane. It is not clear why this is - but one possibility is that where the two P6<sub>1</sub> crystals are joined - in opposite orientations - this Bis-Tris Manganese ion is required on both His C390 and His A390. As the crystals grow away from the merohedral twin plane, both adopt the same asymmetry but in opposite directions (i.e His A390 becomes His C390 in one of the two crystals).</p><p id="P22">This paper has shown how all published type IIA topoisomerase structures are consistent with a single moving metal mechanism. Such a mechanism is presented in an accompanying paper [<xref ref-type="bibr" rid="R49">49</xref>], and current estimates of the probability of each of proposed mechanisms being correct is given in <xref ref-type="table" rid="T4">Table 4</xref>. There are currently three theories (see <xref ref-type="table" rid="T4">Table 4</xref>) of how the G-segment DNA is cleaved by type IIA topoisomerases such as DNA gyrase: (i) a two metal mechanism which was proposed [<xref ref-type="bibr" rid="R42">42</xref>] based on what is clearly, to any experienced technically competent crystallographer (see <xref ref-type="fig" rid="F3">Figure 3</xref>), the misinterpretation of an electron density map [<xref ref-type="bibr" rid="R42">42</xref>]; to date, to the best of our knowledge, there has been no structural data published that is consistent with such a model, it is unlikely to be correct (ii) a single metal mechanism in which DNA-cleavage is proposed to take place when the metal ion 'appears' at the 3'(A) site (described pages 3438-3447 - without a description of how the metal gets to the 3'(A) site) in [<xref ref-type="bibr" rid="R41">41</xref>]. This model is also unlikely to be correct - it seems to ignore normal rules of coordination geometry [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>]. The reason this model was published was because it is difficult to prove it is wrong, and the advice in the paper entitled '<italic>Detect, correct, retract: How to manage incorrect structural model'</italic> had not yet been read [<xref ref-type="bibr" rid="R45">45</xref>].</p><p id="P23">Note that although it is not possible to entirely rule out that the first and second DNA-cleavage steps could have different mechanisms it is difficult to envision how such different mechanisms could have evolved. The first and second DNA-cleavage steps seem likely to use similar mechanisms.</p><p id="P24">The <italic>S.aureus</italic> Greek Key deletion construct has been useful in developing the NBTI class of topoisomerase inhibitors. Indeed, this P6<sub>1</sub> crystal form (see <xref ref-type="table" rid="T1">Table 1</xref> - for details) was initially developed to support the development of gepotidacin. In GlaxoSmithKline the development of the NBTI gepotidacin was problematic because of the general hERG (and other ion channel) inhibition of the class [<xref ref-type="bibr" rid="R59">59</xref>]. The hERG liability of the NBTI class can occasionally be overcome by careful screening of compounds [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R59">59</xref>]. However, virtually all current NBTIs have a basic nitrogen centre flanked by aromatic or hydrophobic groups (<xref ref-type="fig" rid="F6">Figure 6</xref>) - which is a generic pharmacophore description of compounds with a hERG liability [<xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R61">61</xref>]. <xref ref-type="fig" rid="F6">Figure 6</xref> proposes a simple model to explain why the basic nitrogen is usually required in NBTIs. This model proposes that the positive charge on the compound is attracted to the phosphate backbone of the DNA, and then the LHS intercalates. When the DNA is bound by <italic>S. aureus</italic> DNA gyrase the basic nitrogen 'sees' and is attracted too the two Asp 83s. If the RHS is not appropriately positioned it will not have time to enter the pocket on the twofold axis between the two GyrA subunits before the enzyme moves to complete the double-stranded DNA cleavage (see also <xref ref-type="fig" rid="F2">Figure 2</xref> in [<xref ref-type="bibr" rid="R11">11</xref>]). One possibility is that for some enzymes, such as <italic>S. aureus</italic> TopoIV, the compound bound to DNA does not see Asp 83s properly, accounting for weaker activity.</p><p id="P25">If a robust crystal system could be developed suitable for an XChem screen [<xref ref-type="bibr" rid="R62">62</xref>], with the pocket between the two GyrA subunits already open, then fragments containing a RHS but lacking the basic nitrogen might be found. One obvious possibility is to replace the basic nitrogen with a ligand coordinated metal ion; another possibility would be to try and crystallise a complex with the D83N mutant and no RHS on a compound to try to see if this is a realistic proposal.</p></sec><sec id="S8" sec-type="materials | methods"><label>4</label><title>Materials and Methods</title><p id="P26">In the P6<sub>1</sub> crystal form of the <italic>S. aureus</italic> DNA gyrase fusion truncate (see <xref ref-type="table" rid="T1">Table 1</xref>) there is one complex in the asymmetric unit.</p><sec id="S9"><label>4.1</label><title>The standard BA-x nomenclature for <italic>S. aureus</italic> DNA gyrase crystal structures and the Y(B), 3'(A) nomenclature for catalytic metals</title><p id="P27">In <italic>S. aureus</italic> DNA gyrase<sup>CORE</sup> structures the chains are named as B (GyrB) and A (GyrA) from the first gyrase<sup>CORE</sup> fusion truncate subunit, and D (GyrB) and C (GyrA) in the second subunit (we call this nomenclature BA-x for Gyr<underline>B</underline>/Gyr<underline>A</underline> e<underline>x</underline>tended numbering - see also <xref ref-type="supplementary-material" rid="SD1">supplementary discussion</xref> in Bax <italic>et al.</italic>, 2019 [<xref ref-type="bibr" rid="R41">41</xref>]). The DNA-strands standardly have ChainIDs as E and F and each strand contains a total of twenty nucleotides; however, when the DNA is cleaved twelve nucleotides from chain E become covalently attached to tyrosine C123; to easily distinguish between amino acid and nucleotide residues, we add 2000 to nucleotide residue numbers; i.e. E2009-E2020 are nucleotides covalently attached to tyrosine C123 after DNA-cleavage). Similarly for DNAs containing artificial nicks at each DNA-cleavage site (such as 20-12p-8) the eight nucleotides before the nick are numbered E1-E8 (or F1-F8) while those after the nick are numbered E2009-E2020 (or F2009-F2020). Toprim bound metals are given the ChainID of the Toprim domain to which they are bound and the number 5081 (i.e., B5081 – for catalytic metal coordinated by the B GyrB chain, D5081 for the metal coordinated by the D GyrB chain). This nomenclature is used to indicate that in all <italic>S. aureus</italic> DNA gyrase structures solved to date Asp508 from GyrB, moves to coordinate the metal ion whether it occupies the 3'(A) or Y(B) site. One water molecule, which is clearly conserved between the 3'(A) and Y(B) sites, is numbered 5091, and is called 'the inside water molecule'. The coordination sphere for the 3'(A) site includes only two water molecules, 5091 and 5090 (the second molecule contacts GyrB Asp510 and is displaced by it at the B site). In contrast the Y(B) site metal coordination sphere has four water molecules, 5091 and 5093, 5094 and 5095. Water 5095 is displaced by the side-chain oxygen of the catalytic tyrosine (A123 or C123 from GyrA) in the model of DNA-cleavage presented in the accompanying paper [<xref ref-type="bibr" rid="R49">49</xref>].</p><p id="P28">In this paper the Y and 3' nomenclature for the two observed metal binding sites is used because: (i) it avoids confusion with B (GyrB) and A (GyrA) ChainIDs, (ii) in structures with partial occupancy it avoids confusion with the use of alternative position codes A and B (iii) it seems informative of the mechanism (see [<xref ref-type="bibr" rid="R49">49</xref>]) and (iv) it was the original nomenclature proposed in October 2009 for the two sites [<xref ref-type="bibr" rid="R11">11</xref>]. However, we also use throughout the, A=3' and B=Y, site nomenclature in case the reader is more familiar with this naming system for the two metal sites. Having the same names for metal ions and waters involved in catalysis is useful in making movies from more than one structure (see [<xref ref-type="bibr" rid="R49">49</xref>]).</p></sec><sec id="S10"><label>4.2</label><title>Re-refining fully and partially occupied metal binding sites with chemically reasonable geometry</title><p id="P29">To refine a fully occupied metal it is desirable to have 2Å (or better) X-ray data - as this normally allows unambiguous interpretation of 'heavy atom' (carbon, nitrogen, oxygen and heavier elements - but not hydrogen atoms) positions. Between 2.01 and 2.50Å unambiguous interpretation of the water structure around fully occupied metal ions can become ambiguous (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S3</xref> and <xref ref-type="supplementary-material" rid="SD1">S4</xref>) and restraints on metal ion coordination geometry are usually introduced somewhere in this resolution (between 2.01 and 2.50Å) range based on an analysis of small molecule crystal structures [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>]. Lower resolution structures usually cannot clearly define coordination sphere geometry and so restraints must be applied for metal ion coordination spheres in refinement (see for example Wohlkonig <italic>et al</italic>., 2010 [<xref ref-type="bibr" rid="R3">3</xref>], Pan <italic>et al</italic>., 2015 [<xref ref-type="bibr" rid="R9">9</xref>] and Bax <italic>et al</italic>., 2019 [<xref ref-type="bibr" rid="R41">41</xref>]). Because metal ion site coordination geometry can vary - as seen in small molecule crystal structures [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>] - it is desirable to have clear high resolution structures that unambiguously define the coordination sphere for use with lower resolution structures.</p><p id="P30">With partially occupied metal ions refinement is more problematic and the coordination sphere usually needs restraints in refinement. The occupancy of the crystal contact Mn<sup>2+</sup> ions (coordinated by the side-chain of His C390, and mediating a crystal contact via a Bis-Tris buffer molecule - see <xref ref-type="fig" rid="F4">Figure 4</xref>), seems to depend on the protonation state of the histidine 390 side-chain (see <xref ref-type="table" rid="T2">Table 2</xref>). In the initial deposition of 2xcs (2.1Å GSK299423 structure) there was an error in interpreting the electron density at this important crystal contact (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S5</xref> - for initially deposited 2xcs model). Periodic Bond Chain theory [<xref ref-type="bibr" rid="R63">63</xref>] is often applied to crystal growth [<xref ref-type="bibr" rid="R64">64</xref>]; however, most crystals do not grow as a pair of merohedral twins from a common plane perpendicular to the 61 axis; the initiation step from this common plane may require both BisTris and Mn<sup>2+</sup> ions for the initiation of the growth of this P6<sub>1</sub> crystal form (<xref ref-type="table" rid="T1">Table 1</xref>) of the <italic>S.aureus</italic> fusion truncate in complexes with DNA even in the presence of crystal seeds.</p><p id="P31">The structure factors for four structures we re-refined (PDB codes: 2xcs, 5cdm, 5iwi, 5cdr) were retrieved from the protein data bank (PDB) and converted to .mtz files with the CCP4 program cif2mtz [<xref ref-type="bibr" rid="R65">65</xref>]. These four structures were re-refined (see <xref ref-type="supplementary-material" rid="SD1">supplementary Table S1</xref>) to correct a crystal contact error; this confirmed the accuracy of the catalytic metal-ion coordination geometry in these crystal structures. To confirm the presence of manganese ions at the crystal contact site an anomalous dataset was collected which showed the expected anomalous peaks for the two catalytic metals and a weaker peak for the partially occupied crystal contact metal ion (see <xref ref-type="fig" rid="F4">figure 4</xref>). However, it unexpectedly also showed anomalous peaks close to the position seen in quinolone complexes (see <xref ref-type="table" rid="T3">Table 3</xref>). The anomalous dataset was collected from a binary complex with a doubly nicked twenty base-pair DNA duplex (20-12p-8); the 5'-phosphate on the 12mer [<xref ref-type="bibr" rid="R66">66</xref>] was thought to be responsible for the observation of partially occupied manganese sites close to those observed in the water metal-ion bridge in the moxifloxacin structure [<xref ref-type="bibr" rid="R9">9</xref>]. The 2.65Å 5cdr model with the same doubly nicked 20-12p-8 was re-refined to include partially occupied Mn<sup>2+</sup> ions E1999 and F1999 (<underline><styled-content style="color:#8B8BFF">5cdr-v2-BA-x.pdb</styled-content></underline>).</p><p id="P32">The P6<sub>1</sub> structures re-refined (see <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>) include the 2.1Å structure with GSK299423 (pdb code: 2xcs) - the highest resolution unambiguous 3'(A) site structure (<xref ref-type="fig" rid="F1">Figure 1</xref>). This was re-refined without restraints on Mn<sup>2+</sup> geometry. Although the 2.5Å QPT-1 structure (pdb code: 5cdm) clearly has 'the same' Y(B) coordination geometry as in the 2.16Å human top IIβ structure with etoposide and magnesium ions [<xref ref-type="bibr" rid="R67">67</xref>] (see <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S4</xref>), restraints were needed on the metal ion geometry in re-refining this 2.5Å QPT-1 structure. Restraints were also used in re-refining the catalytic metals in 5iwi - a 1.98Å structure in which the catalytic metal ions (Mn<sup>2+</sup>) are complicated by static disorder around the twofold axis, analogous to that seen in 3l4k.</p><p id="P33">The 5cdr structure was re-refined because the 2.58Å anomalous dataset, collected at the manganese K edge (6.6KeV = 1.8785Å), was collected on a crystal grown in similar conditions to 5cdr. Electron density, previously interpreted (in 5cdr) as a glycerol molecule, is now interpreted as a partially occupied Mn<sup>2+</sup> ion and coordinating waters (<underline><styled-content style="color:#8B8BFF">5cdr-v2-BA-x.pdb</styled-content></underline>). The lack of a high resolution fully occupied Mn<sup>2+</sup> ions for this site (near Ser 84) means this interpretation is not definitive.</p><p id="P34">Refinement of a protein structure is never complete; it is only stopped when time and publication dictates. The details of re-refined coordinates, re-refined with Refmac5/Servalcat [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R68">68</xref>] are described in <xref ref-type="supplementary-material" rid="SD1">supplementary Table S1</xref>. In normal protein crystal refinement, a solvent correction is applied which assumes the non-defined parts of the structure have the same solvent electron density value. It is noted that for <italic>S.aureus</italic> DNA gyrase crystals used in this paper - most crystals are grown in an excess of DNA; although there is no clear electron density for this DNA it may be present as the T-segment in disordered solvent regions. This could account for higher R-factors seen with low resolution (~40-20Å) data. In our experience the low-resolution shells of data usually give R-factors with normal protein crystals, after solvent correction, of less than 20%, with DNA gyrase the R-factors in these low-resolution shells (between 40Å and 20Å) tend to be between 20 and 30%. For this reason, a low-resolution cutoff of 18 or 20Å is usually employed in refinement (see <xref ref-type="supplementary-material" rid="SD1">supplementary Table S1</xref>). The solvent region, in DNA gyrase crystals grown in an excess of 20mer duplex DNA, is not necessarily of uniform electron density.</p></sec><sec id="S11"><label>4.3</label><title>Protein Purification and Crystallisation of a DNA gyrase – DNA complex</title><p id="P35">The <italic>S. aureus</italic> DNA gyrase fusion truncate B27:A56 Y123F (GKdel) (M<sub>w</sub> 78,020) was was purchased from Inspiralis. It was expressed in <italic>E. coli</italic> and purified according to the protocol described in [<xref ref-type="bibr" rid="R11">11</xref>] with modifications described below, The purified protein was concentrated to 12 mg/mL and stored in a storage buffer (20 mM HEPES pH 7.0, 5 mM MnCl<sub>2</sub> and 100 mM Na<sub>2</sub>SO<sub>4</sub>). The DNA oligonucleotide used in crystallisations for anomalous data collection, 20-12p-8, was from Eurogentec (Seraing, Belgium). The lyophilized DNA was resuspended in nuclease free dH2O and annealed from 86°C to 24°C over 45 minutes to give an artificially nicked DNA duplex at a concentration of 2 mM.</p><p id="P36">Crystallisation complexes were formed by mixing protein, HEPES buffer and DNA, then incubating on ice for 1 hour. Crystals of <italic>S. aureus</italic> DNA GyrB27:A56 Y123F with 20-12p-8 DNA (binary complexes) were grown by the microbatch under oil method, with streak seeding from a seedstock. Seed stock was produced by crushing 3 hexagonal rod-shaped <italic>S. aureus</italic> GyrB27:A56 Y123F (GKdel)/20-12p-8 crystals in 50 µL of crystallisation buffer. A crystallisation screen consisting of Bis-Tris buffer pH 5.9-6.4 (90, 150 mM) and PEG 5kMME (7-14%) was made. For a single drop, 1 µL of the complex mixture was mixed with 1 µL of crystallisation buffer in a 72-well Terasaki microbatch plate, streak seeded with a whisker dipped in the seed stock, then covered in 2-3 mL of paraffin oil. The plates were incubated at 20°C and crystal growth was observed between 1 and 14 days. The crystal which gave the 2.58 Å dataset was grown from a crystallisation drop consisting of 1 µL protein mixture (0.0424 mM <italic>S. aureus</italic> DNA GyrB27:A56 Y123F, 0.122 mM 20-12p-8 DNA duplex, 2.755 mM MnCl<sub>2</sub> and 20 mM HEPES) with 1 µL crystallisation buffer (150 mM BisTris pH 6.1 and 12% PEG 5kMME). A single hexagonal-rod shaped crystal was transferred to a cryobuffer (15% glycerol, 19% PEG 5kMME and 150 mM Bis-Tris) before flash-cooling and storage in liquid nitrogen for data collection.</p></sec><sec id="S12"><label>4.4</label><title>Data Collection, Structure Determination and Refinement</title><p id="P37">The presence of Manganese (Mn) was confirmed by taking a fluorescence spectrum. Data was collected on the long-wavelength beamline I23 [<xref ref-type="bibr" rid="R69">69</xref>] at Diamond Light Source (Oxfordshire, UK), at two wavelengths: 1.33 Å (E = 6.6 keV, above the Mn K-edge) and 2.75 Å (E = 4.5 keV). The shorter wavelength (λ = 1.33 Å) was chosen to maximise the anomalous signal from Mn while the aim for the longer wavelength (λ = 2.75 Å) was to provide increased anomalous scattering from the phosphorus atoms on the DNA backbone [<xref ref-type="bibr" rid="R47">47</xref>], to aid model building in sections of poor-quality electron density.</p><p id="P38">Three 360° datasets were measured alternatively, at each energy, using the kappa goniometry to change the orientation of the crystal and increase the multiplicity of the data. The γ = 1.33 Å and the γ = 2.75 Å data were collected using 100 % and 55 % beam transmission, respectively, with an exposure of 0.1s per 0.1° rotation. Data integration and scaling was performed with autoPROC [<xref ref-type="bibr" rid="R70">70</xref>], using a I/sI cut-off &gt; 1.0 and CC<sub>1/2</sub> &gt; 0.3 (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). The structure was refined with refmac [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R68">68</xref>] starting from a structurally similar model (<xref ref-type="supplementary-material" rid="SD1">Table S3</xref> - for refinement statistics) containing the same <italic>S. aureus</italic> DNA GyrB27:A56 Y123F protein and 20-12p-8 artificially nicked DNA (PDB code: 5cdr). As the data were severely twinned (twin fraction = 0.51, twin law = -K,-H,-L) twin refinement was necessary and restraints for bond length (2.17 Å) and bond angles (90, 180°) were used to accommodate an octahedral Mn<sup>2+</sup> coordination geometry for the five Mn sites. Model building was performed with Coot [<xref ref-type="bibr" rid="R71">71</xref>]. As with most previous <italic>S.aureus</italic> DNA gyrase structures without compound (binary complexes with doubly nicked DNAs), there was considerable difficulty in building the four central DNA base pairs bridging the DNA cleavage sites. The final refined model was used for f” refinement in Phenix [<xref ref-type="bibr" rid="R58">58</xref>], with only ’anomalous groups’ refinement switched on, starting from a f” value of 0. Anomalous difference Fourier maps were generated in Phenix.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary tables and figures</label><media xlink:href="EMS199524-supplement-Supplementary_tables_and_figures.pdf" mimetype="application" mime-subtype="pdf" id="d56aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S13"><title>Acknowledgments</title><p>We thank Halina Mikalojek for help with crystallisation experiments.</p><sec id="S14"><title>Funding</title><p>“This research was funded by a Medicines Discovery Institute/Diamond Light Source PhD to H.M., and F.L. and G.N.M. are supported by MRC grant No. MC_UP_A025_1012. R.A.N. is supported by the Science and Technology Facilities Council (STFC), part of UK Research and Innovation (UKRI), and was supported by BBSRC grant No. BB/S007083/1.”</p></sec></ack><sec id="S15" sec-type="data-availability"><title>Data Availability Statement</title><p id="P39">Structure factors and 'original' coordinates with standard PDB nomenclature are available from the protein databank (PDB); including the those for 9fz6. Coordinates with standard BA-x nomenclature are available at <ext-link ext-link-type="uri" xlink:href="https://profiles.cardiff.ac.uk/staff/baxb">https://profiles.cardiff.ac.uk/staff/baxb</ext-link> - click on 'research' tab - and scroll down to download 'required' coordinates.</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P40"><bold>Author Contributions:</bold> “Conceptualization, H.M. and B.D.B.; methodology, H.M., A.J.W., R.D., and B.D.B.; software, R.A.N., F.L., and G.M.; validation, H.M., R.D., and B.D.B.; formal analysis, H.M., A.J.W., R.D.; investigation, H.M and B.D.B.; resources, A.J.W., S.E.W., G.E. and R.D.; data curation, H.M.; writing—original draft preparation, H.M and B.D.B.; writing—review and editing, All authors.; visualization, H.M and B.D.B.; supervision, A.J.W., S.E.W., G.E, and B.D.B; project administration, A.J.W and B.D.B..; funding acquisition, R.A.N., S.E.W. and G.E. All authors have read and agreed to the published version of the manuscript.”</p></fn><fn id="FN2"><p id="P41"><bold>Institutional Review Board Statement:</bold> “Not applicable”</p></fn><fn id="FN3" fn-type="conflict"><p id="P42"><bold>Conflicts of Interest:</bold> “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results”.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Association of US Food and Drug Administration removal of indications for use of oral quinolones with prescribing trends</article-title><source>JAMA internal medicine</source><year>2021</year><volume>181</volume><issue>6</issue><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="pmcid">PMC8056313</pub-id><pub-id pub-id-type="pmid">33871571</pub-id><pub-id pub-id-type="doi">10.1001/jamainternmed.2021.1154</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>DC</given-names></name><name><surname>Jacoby</surname><given-names>GA</given-names></name></person-group><article-title>Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance</article-title><source>Cold Spring Harbor perspectives in medicine</source><year>2016</year><volume>6</volume><issue>9</issue><elocation-id>a025320</elocation-id><pub-id pub-id-type="pmcid">PMC5008060</pub-id><pub-id pub-id-type="pmid">27449972</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a025320</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlkonig</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance</article-title><source>Nat Struct Mol Biol</source><year>2010</year><volume>17</volume><issue>9</issue><fpage>1152</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">20802486</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model</article-title><source>Frontiers in Pharmacology</source><year>2023</year><volume>14</volume><pub-id pub-id-type="pmcid">PMC10733441</pub-id><pub-id pub-id-type="pmid">38130409</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1291885</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>TM</given-names></name><etal/></person-group><chapter-title>2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection</chapter-title><source>Open Forum Infectious Diseases</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc><year>2023</year></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase</article-title><source>ACS Infect Dis</source><year>2019</year><volume>5</volume><issue>4</issue><fpage>570</fpage><lpage>581</lpage><pub-id pub-id-type="pmcid">PMC6461504</pub-id><pub-id pub-id-type="pmid">30757898</pub-id><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00315</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</article-title><source>Antimicrob Agents Chemother</source><year>2008</year><volume>52</volume><issue>8</issue><fpage>2806</fpage><lpage>2812</lpage><pub-id pub-id-type="pmcid">PMC2493097</pub-id><pub-id pub-id-type="pmid">18519725</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00247-08</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>H</given-names></name><etal/></person-group><article-title>A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase</article-title><source>International Journal of Molecular Sciences</source><year>2023</year><volume>24</volume><issue>2</issue><elocation-id>1634</elocation-id><pub-id pub-id-type="pmcid">PMC9865888</pub-id><pub-id pub-id-type="pmid">36675148</pub-id><pub-id pub-id-type="doi">10.3390/ijms24021634</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><elocation-id>10048</elocation-id><pub-id pub-id-type="pmcid">PMC4686662</pub-id><pub-id pub-id-type="pmid">26640131</pub-id><pub-id pub-id-type="doi">10.1038/ncomms10048</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blower</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><issue>7</issue><fpage>1706</fpage><lpage>1713</lpage><pub-id pub-id-type="pmcid">PMC4763791</pub-id><pub-id pub-id-type="pmid">26792525</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1525047113</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Type IIA topoisomerase inhibition by a new class of antibacterial agents</article-title><source>Nature</source><year>2010</year><volume>466</volume><issue>7309</issue><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">20686482</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dadgostar</surname><given-names>P</given-names></name></person-group><article-title>Antimicrobial resistance: implications and costs</article-title><source>Infection and drug resistance</source><year>2019</year><fpage>3903</fpage><lpage>3910</lpage><pub-id pub-id-type="pmcid">PMC6929930</pub-id><pub-id pub-id-type="pmid">31908502</pub-id><pub-id pub-id-type="doi">10.2147/IDR.S234610</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Founou</surname><given-names>RC</given-names></name><name><surname>Founou</surname><given-names>LL</given-names></name><name><surname>Essack</surname><given-names>SY</given-names></name></person-group><article-title>Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis</article-title><source>PloS one</source><year>2017</year><volume>12</volume><issue>12</issue><elocation-id>e0189621</elocation-id><pub-id pub-id-type="pmcid">PMC5739407</pub-id><pub-id pub-id-type="pmid">29267306</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189621</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llor</surname><given-names>C</given-names></name><name><surname>Bjerrum</surname><given-names>L</given-names></name></person-group><article-title>Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem</article-title><source>Therapeutic advances in drug safety</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>229</fpage><lpage>241</lpage><pub-id pub-id-type="pmcid">PMC4232501</pub-id><pub-id pub-id-type="pmid">25436105</pub-id><pub-id pub-id-type="doi">10.1177/2042098614554919</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestinaci</surname><given-names>F</given-names></name><name><surname>Pezzotti</surname><given-names>P</given-names></name><name><surname>Pantosti</surname><given-names>A</given-names></name></person-group><article-title>Antimicrobial resistance: a global multifaceted phenomenon</article-title><source>Pathogens and global health</source><year>2015</year><volume>109</volume><issue>7</issue><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmcid">PMC4768623</pub-id><pub-id pub-id-type="pmid">26343252</pub-id><pub-id pub-id-type="doi">10.1179/2047773215Y.0000000030</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="book"><collab>European Centre for Disease Prevention and Control Collaborative G</collab><source>Antimicrobial resistance surveillance in Europe 2023 - 2021 data</source><publisher-name>European Centre for Disease Prevention and Control</publisher-name><year>2023</year><fpage>186</fpage></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allocati</surname><given-names>N</given-names></name><etal/></person-group><article-title>Escherichia coli in Europe: an overview</article-title><source>International journal of environmental research and public health</source><year>2013</year><volume>10</volume><issue>12</issue><fpage>6235</fpage><lpage>6254</lpage><pub-id pub-id-type="pmcid">PMC3881111</pub-id><pub-id pub-id-type="pmid">24287850</pub-id><pub-id pub-id-type="doi">10.3390/ijerph10126235</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manaia</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The Complex interplay between antibiotic resistance and pharmaceutical and personal care products in the environment</article-title><source>Environmental Toxicology and Chemistry</source><year>2024</year><volume>43</volume><issue>3</issue><fpage>637</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">36582150</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagenlehner</surname><given-names>F</given-names></name><etal/></person-group><article-title>Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials</article-title><source>The Lancet</source><year>2024</year><pub-id pub-id-type="pmid">38342126</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>19</issue><fpage>1835</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">30403954</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan-Blitz</surname><given-names>L-T</given-names></name><name><surname>Fifer</surname><given-names>H</given-names></name><name><surname>Klausner</surname><given-names>JD</given-names></name></person-group><article-title>Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions</article-title><source>The Lancet Infectious Diseases</source><year>2024</year><pub-id pub-id-type="pmcid">PMC11391204</pub-id><pub-id pub-id-type="pmid">38367636</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00001-X</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oviatt</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Interactions between Gepotidacin and Escherichia coli Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting</article-title><source>ACS Infectious Diseases</source><year>2024</year><pub-id pub-id-type="pmcid">PMC11015057</pub-id><pub-id pub-id-type="pmid">38606465</pub-id><pub-id pub-id-type="doi">10.1021/acsinfecdis.3c00346</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoeffler</surname><given-names>AJ</given-names></name><name><surname>Berger</surname><given-names>JM</given-names></name></person-group><article-title>DNA topoisomerases: harnessing and constraining energy to govern chromosome topology</article-title><source>Q Rev Biophys</source><year>2008</year><volume>41</volume><issue>1</issue><fpage>41</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">18755053</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>AD</given-names></name><name><surname>Maxwell</surname><given-names>A</given-names></name></person-group><source>DNA topology</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>USA</publisher-loc><year>2005</year></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pommier</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Roles of eukaryotic topoisomerases in transcription, replication and genomic stability</article-title><source>Nat Rev Mol Cell Biol</source><year>2016</year><volume>17</volume><issue>11</issue><fpage>703</fpage><lpage>721</lpage><pub-id pub-id-type="pmcid">PMC9248348</pub-id><pub-id pub-id-type="pmid">27649880</pub-id><pub-id pub-id-type="doi">10.1038/nrm.2016.111</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Novel tricyclics (eg, GSK945237) as potent inhibitors of bacterial type IIA topoisomerases</article-title><source>Bioorganic &amp; medicinal chemistry letters</source><year>2016</year><volume>26</volume><issue>10</issue><fpage>2464</fpage><lpage>2469</lpage><pub-id pub-id-type="pmid">27055939</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases</article-title><source>Bioorg Med Chem Lett</source><year>2013</year><volume>23</volume><issue>19</issue><fpage>5437</fpage><lpage>5441</lpage><pub-id pub-id-type="pmid">23968823</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6)</article-title><source>Bioorg Med Chem Lett</source><year>2015</year><volume>25</volume><issue>17</issue><fpage>3636</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">26141771</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents</article-title><source>ACS Med Chem Lett</source><year>2014</year><volume>5</volume><issue>5</issue><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="pmcid">PMC4027601</pub-id><pub-id pub-id-type="pmid">24900889</pub-id><pub-id pub-id-type="doi">10.1021/ml500069w</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magarò</surname><given-names>G</given-names></name><etal/></person-group><article-title>Virtual Screening Approach and Investigation of Structure–Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens</article-title><source>Journal of Medicinal Chemistry</source><year>2019</year><volume>62</volume><issue>16</issue><fpage>7445</fpage><lpage>7472</lpage><pub-id pub-id-type="pmid">31276392</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumming</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens</article-title><source>ACS Medicinal Chemistry Letters</source><year>2023</year><pub-id pub-id-type="pmcid">PMC10350941</pub-id><pub-id pub-id-type="pmid">37465290</pub-id><pub-id pub-id-type="doi">10.1021/acsmedchemlett.3c00187</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Optimization of TopoIV potency, ADMET properties, and hERG inhibition of 5-amino-1, 3-dioxane-linked novel bacterial topoisomerase inhibitors: Identification of a lead with in vivo efficacy against MRSA</article-title><source>Journal of Medicinal Chemistry</source><year>2021</year><volume>64</volume><issue>20</issue><fpage>15214</fpage><lpage>15249</lpage><pub-id pub-id-type="pmid">34614347</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germe</surname><given-names>T</given-names></name><etal/></person-group><article-title>A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>8</issue><fpage>4114</fpage><lpage>4128</lpage><pub-id pub-id-type="pmcid">PMC5934632</pub-id><pub-id pub-id-type="pmid">29596599</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky241</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>B</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Edge</surname><given-names>C</given-names></name></person-group><article-title>Getting the chemistry right: protonation, tautomers and the importance of H atoms in biological chemistry</article-title><source>Acta Crystallogr D Struct Biol</source><year>2017</year><volume>73</volume><issue>Pt 2</issue><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmcid">PMC5297916</pub-id><pub-id pub-id-type="pmid">28177309</pub-id><pub-id pub-id-type="doi">10.1107/S2059798316020283</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Using photocaging for fast time-resolved structural biology studies</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2021</year><volume>77</volume><issue>10</issue><fpage>1218</fpage><lpage>1232</lpage><pub-id pub-id-type="pmcid">PMC8489231</pub-id><pub-id pub-id-type="pmid">34605426</pub-id><pub-id pub-id-type="doi">10.1107/S2059798321008809</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>PR</given-names></name></person-group><article-title>Raman crystallography and other biochemical applications of Raman microscopy</article-title><source>Annu Rev Phys Chem</source><year>2006</year><volume>57</volume><fpage>527</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">16599820</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>AR</given-names></name><name><surname>Mehrabi</surname><given-names>P</given-names></name></person-group><article-title>Serial synchrotron crystallography for time-resolved structural biology</article-title><source>Curr Opin Struct Biol</source><year>2020</year><volume>65</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">32846363</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><issue>22</issue><fpage>E4492</fpage><lpage>e4500</lpage><pub-id pub-id-type="pmcid">PMC5465892</pub-id><pub-id pub-id-type="pmid">28507124</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1700721114</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thalji</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Structure-guided design of antibacterials that allosterically inhibit DNA gyrase</article-title><source>Bioorg Med Chem Lett</source><year>2019</year><volume>29</volume><issue>11</issue><fpage>1407</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">30962087</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolaric</surname><given-names>A</given-names></name><etal/></person-group><article-title>Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>150</fpage><pub-id pub-id-type="pmcid">PMC7794245</pub-id><pub-id pub-id-type="pmid">33420011</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-20405-8</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>BD</given-names></name><etal/></person-group><article-title>DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion</article-title><source>J Mol Biol</source><year>2019</year><volume>431</volume><issue>18</issue><fpage>3427</fpage><lpage>3449</lpage><pub-id pub-id-type="pmcid">PMC6723622</pub-id><pub-id pub-id-type="pmid">31301408</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2019.07.008</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>BH</given-names></name><etal/></person-group><article-title>A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases</article-title><source>Nature</source><year>2010</year><volume>465</volume><issue>7298</issue><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="pmcid">PMC2882514</pub-id><pub-id pub-id-type="pmid">20485342</pub-id><pub-id pub-id-type="doi">10.1038/nature08974</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Manganese as a Replacement for Magnesium and Zinc: Functional Comparison of the Divalent Ions</article-title><source>J Am Chem Soc</source><year>1999</year><volume>121</volume><fpage>7360</fpage><lpage>7372</lpage></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Calcium ion coordination: a comparison with that of beryllium, magnesium, and zinc</article-title><source>Journal of the American Chemical Society</source><year>1996</year><volume>118</volume><issue>24</issue><fpage>5752</fpage><lpage>5763</lpage></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wlodawer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Detect, correct, retract: How to manage incorrect structural models</article-title><source>The FEBS journal</source><year>2018</year><volume>285</volume><issue>3</issue><fpage>444</fpage><lpage>466</lpage><pub-id pub-id-type="pmcid">PMC5799025</pub-id><pub-id pub-id-type="pmid">29113027</pub-id><pub-id pub-id-type="doi">10.1111/febs.14320</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>K</given-names></name><etal/></person-group><article-title>GEMMI and Servalcat restrain REFMAC5</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2023</year><volume>79</volume><issue>5</issue><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="pmcid">PMC10167671</pub-id><pub-id pub-id-type="pmid">37158197</pub-id><pub-id pub-id-type="doi">10.1107/S2059798323002413</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Omari</surname><given-names>K</given-names></name><etal/></person-group><article-title>Utilizing anomalous signals for element identification in macromolecular crystallography</article-title><source>Biological Crystallography</source><year>2024</year><volume>80</volume><issue>10</issue><pub-id pub-id-type="pmcid">PMC11448921</pub-id><pub-id pub-id-type="pmid">39291627</pub-id><pub-id pub-id-type="doi">10.1107/S2059798324008659</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masmaliyeva</surname><given-names>RC</given-names></name><name><surname>Babai</surname><given-names>KH</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name></person-group><article-title>Local and global analysis of macromolecular atomic displacement parameters</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2020</year><volume>76</volume><issue>10</issue><fpage>926</fpage><lpage>937</lpage><pub-id pub-id-type="pmcid">PMC7543658</pub-id><pub-id pub-id-type="pmid">33021494</pub-id><pub-id pub-id-type="doi">10.1107/S2059798320011043</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>RA</given-names></name><etal/></person-group><article-title>How do gepotidacin and zolifodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 2. A Single Moving Metal Mechanism</article-title><source>Bioarchives</source><year>2024</year></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucher</surname><given-names>D</given-names></name><name><surname>Stouten</surname><given-names>P</given-names></name><name><surname>Triballeau</surname><given-names>N</given-names></name></person-group><article-title>Shedding light on important waters for drug design: simulations versus grid-based methods</article-title><source>Journal of Chemical Information and Modeling</source><year>2018</year><volume>58</volume><issue>3</issue><fpage>692</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">29489352</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Garcia</surname><given-names>D</given-names></name><name><surname>Barril</surname><given-names>X</given-names></name></person-group><article-title>Molecular simulations with solvent competition quantify water displaceability and provide accurate interaction maps of protein binding sites</article-title><source>Journal of medicinal chemistry</source><year>2014</year><volume>57</volume><issue>20</issue><fpage>8530</fpage><lpage>8539</lpage><pub-id pub-id-type="pmid">25275946</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="book"><source>The PyMOL Molecular Graphics System, Version 1.5.0.4</source><publisher-name>Schrödinger, LLC</publisher-name><year>2013</year></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deweese</surname><given-names>JE</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name></person-group><article-title>The use of divalent metal ions by type II topoisomerases</article-title><source>Metallomics</source><year>2010</year><volume>2</volume><issue>7</issue><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="pmcid">PMC2918885</pub-id><pub-id pub-id-type="pmid">20703329</pub-id><pub-id pub-id-type="doi">10.1039/c003759a</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deweese</surname><given-names>JE</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name></person-group><article-title>The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing</article-title><source>Nucleic Acids Res</source><year>2009</year><volume>37</volume><issue>3</issue><fpage>738</fpage><lpage>748</lpage><pub-id pub-id-type="pmcid">PMC2647315</pub-id><pub-id pub-id-type="pmid">19042970</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkn937</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deweese</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><issue>38</issue><fpage>8940</fpage><lpage>8947</lpage><pub-id pub-id-type="pmcid">PMC2782489</pub-id><pub-id pub-id-type="pmid">19697956</pub-id><pub-id pub-id-type="doi">10.1021/bi900875c</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deweese</surname><given-names>JE</given-names></name><name><surname>Burgin</surname><given-names>AB</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name></person-group><article-title>Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><issue>15</issue><fpage>4883</fpage><lpage>4893</lpage><pub-id pub-id-type="pmcid">PMC2528187</pub-id><pub-id pub-id-type="pmid">18653531</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkn466</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorn</surname><given-names>A</given-names></name><name><surname>Sheldrick</surname><given-names>GM</given-names></name></person-group><article-title>ANODE: anomalous and heavy-atom density calculation</article-title><source>Journal of applied crystallography</source><year>2011</year><volume>44</volume><issue>6</issue><fpage>1285</fpage><lpage>1287</lpage><pub-id pub-id-type="pmcid">PMC3246834</pub-id><pub-id pub-id-type="pmid">22477786</pub-id><pub-id pub-id-type="doi">10.1107/S0021889811041768</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallogr D Struct Biol</source><year>2019</year><volume>75</volume><issue>Pt 10</issue><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="pmcid">PMC6778852</pub-id><pub-id pub-id-type="pmid">31588918</pub-id><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolaric</surname><given-names>A</given-names></name><name><surname>Minovski</surname><given-names>N</given-names></name></person-group><article-title>Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity</article-title><source>Future Med Chem</source><year>2018</year><volume>10</volume><issue>19</issue><fpage>2241</fpage><lpage>2244</lpage><pub-id pub-id-type="pmid">30215281</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>TK</given-names><suffix>Jr</suffix></name><name><surname>Sullivan</surname><given-names>ME</given-names></name></person-group><article-title>2 An Overview of Class III Electrophysiological Agents: A New Generation of Antiarrhythmic Therapy</article-title><source>Progress in medicinal chemistry</source><year>1992</year><volume>29</volume><fpage>65</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">1475373</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>Y</given-names></name><etal/></person-group><article-title>In silico prediction of hERG inhibition</article-title><source>Future medicinal chemistry</source><year>2015</year><volume>7</volume><issue>5</issue><fpage>571</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">25921399</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douangamath</surname><given-names>A</given-names></name><etal/></person-group><article-title>Achieving efficient fragment screening at XChem facility at diamond light source</article-title><source>JoVE (Journal of Visualized Experiments)</source><year>2021</year><issue>171</issue><elocation-id>e62414</elocation-id><pub-id pub-id-type="pmid">34125095</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>P</given-names></name><name><surname>Perdok</surname><given-names>W</given-names></name></person-group><article-title>On the relations between structure and morphology of crystals: I</article-title><source>Acta Crystallographica</source><year>1955</year><volume>8</volume><fpage>49</fpage><lpage>52</lpage></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>M</given-names></name><name><surname>Genovesio-Taverne</surname><given-names>J-C</given-names></name><name><surname>Fontecilla-Camps</surname><given-names>JC</given-names></name></person-group><article-title>Application of the periodic bond chain (PBC) theory to the analysis of the molecular packing in protein crystals</article-title><source>Journal of Crystal Growth</source><year>1988</year><volume>90</volume><issue>1–3</issue><fpage>245</fpage><lpage>258</lpage></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agirre</surname><given-names>J</given-names></name><etal/></person-group><article-title>The CCP4 suite: integrative software for macromolecular crystallography</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2023</year><volume>79</volume><issue>6</issue><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="pmcid">PMC10233625</pub-id><pub-id pub-id-type="pmid">37259835</pub-id><pub-id pub-id-type="doi">10.1107/S2059798323003595</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikannathasan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide</article-title><source>Acta Crystallographica Section F: Structural Biology Communications</source><year>2015</year><volume>71</volume><issue>10</issue><fpage>1242</fpage><lpage>1246</lpage><pub-id pub-id-type="pmcid">PMC4601586</pub-id><pub-id pub-id-type="pmid">26457513</pub-id><pub-id pub-id-type="doi">10.1107/S2053230X15015290</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide</article-title><source>Science</source><year>2011</year><volume>333</volume><issue>6041</issue><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">21778401</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>GN</given-names></name><etal/></person-group><article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2011</year><volume>67</volume><issue>Pt 4</issue><fpage>355</fpage><lpage>67</lpage><pub-id pub-id-type="pmcid">PMC3069751</pub-id><pub-id pub-id-type="pmid">21460454</pub-id><pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>A</given-names></name><etal/></person-group><article-title>In-vacuum long-wavelength macromolecular crystallography</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2016</year><volume>72</volume><issue>3</issue><fpage>430</fpage><lpage>439</lpage><pub-id pub-id-type="pmcid">PMC4784674</pub-id><pub-id pub-id-type="pmid">26960130</pub-id><pub-id pub-id-type="doi">10.1107/S2059798316001078</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonrhein</surname><given-names>C</given-names></name><etal/></person-group><article-title>Data processing and analysis with the autoPROC toolbox</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2011</year><volume>67</volume><issue>Pt4</issue><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmcid">PMC3069744</pub-id><pub-id pub-id-type="pmid">21460447</pub-id><pub-id pub-id-type="doi">10.1107/S0907444911007773</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><etal/></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2010</year><volume>66</volume><issue>Pt 4</issue><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="pmcid">PMC2852313</pub-id><pub-id pub-id-type="pmid">20383002</pub-id><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Comparison of the structure of GSK299423 (2xcs-v2-BA-x.pdb) with that of QPT-1 (5cdm-v2-BA-x.pdb).</title><p><bold>(a)</bold> The 2.1Å crystal structure of GSK299423 includes a single Mn<sup>2+</sup> ion at each active site at the 3' (A) position (in contact with the 3' oxygen - red arrow). If the DNA were cleaved the bond between the 3'oxygen and the phosphorous atom would be cleaved (see panel b). For clarity only one GSK299423 molecule is shown on the twofold axis of the complex. (<bold>b)</bold> In the 2.5Å QPT-1 structure a single metal ion is seen at the Y (or B) position. This is called the Y site because it seems likely the catalytic tyrosine (Y123) comes into this site as a tyrosinate ion (negative charge on terminal oxygen) occupying a similar position to water 5095 (see [<xref ref-type="bibr" rid="R49">49</xref>]). The position(s) of the 3' oxygen (OH) and phosphorous atom are indicated by red and black arrow(s). Molecular figures generated with Pymol [<xref ref-type="bibr" rid="R52">52</xref>].</p></caption><graphic xlink:href="EMS199524-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Comparison of metal coordination geometry in the 2.1Å GSK299423 (2xcs-v2-BA-x.pdb) structure with that in QPT-1 (5cdm-v2-BA-x.pdb).</title><p><bold>(a)</bold> The 2.1Å crystal structure of GSK299423 shows a single Mn<sup>2+</sup> at the 3' (A) position (in contact with the 3' oxygen - red arrow). If the DNA were cleaved the bond between the 3'oxygen (<underline><styled-content style="color:#ED2224">red arrow</styled-content></underline>) and the phosphorous atom (black arrow) would be cleaved. (<bold>b)</bold> In the 2.5Å QT-1 structure a single metal ion is seen at the Y (B) position. This is called the Y site because the catalytic tyrosine (Y123) comes into this site as a tyrosinate ion (-ve charge on terminal oxygen) occupying a similar position to water 5095 for DNA-cleavage (see [<xref ref-type="bibr" rid="R49">49</xref>]). Oxygens directly coordinating the catalytic metal ion are shown as small spheres, as is the 3' oxygen (<underline><styled-content style="color:#ED2224">arrowed</styled-content></underline>). (<bold>c</bold>) Panels a and b are shown superposed.</p></caption><graphic xlink:href="EMS199524-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Comparison of metal coordination geometry in the 2.98Å deposited 3l4k with that in re-refined 3l4k.</title><p><bold>(a,b)</bold> The two active sites in the originally deposited coordinates are different (occupancies 0.5) but the deposited metals have occupancy 1.0 implying that the authors believe the metal geometry is unaffected by the presence or absence of the scissile phosphate at the active site. <bold>(c,d)</bold> In the re-refined coordinates the presence of the scissile phosphate at the active site (in <bold>c</bold>) attracts a metal ion (zinc) which is octahedrally coordinated by an oxygen from the scissile phosphate, the 3' sulfur (3'S), oxygens from E449 and D526 and two waters. This metal is at the 3' site. In panel <bold>d</bold> the absence of the scissile phosphate means the metal ion is seen at the Y(B) position.</p></caption><graphic xlink:href="EMS199524-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Structure and map at 2.58 Å.</title><p>In one asymmetric unit, 5 x Mn<sup>2+</sup> were seen in the f” refined anomalous difference Fourier map (contoured at 4 s - shown in yellow - note the density for the second catalytic metal is obscured by protein structure in this view). Inset anomalous density for BisTris coordinated Mn<sup>2+</sup> bridging between two asymmetric units at a P6<sub>1</sub> crystal contact.</p></caption><graphic xlink:href="EMS199524-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Experimental anomalous difference Fourier maps.</title><p>Calculated in <italic>phenix.refine</italic> [<xref ref-type="bibr" rid="R58">58</xref>] using data collected at 4.5 <italic>k</italic>eV and 6.6 <italic>k</italic>eV (manganese K-edge), to confirm the presence of manganese and to aid in the refinement of DNA bases. The 4.5 <italic>k</italic>eV map is contoured to 5.5 σ (green) and the 6.6 <italic>k</italic>eV map to 6.5 σ (yellow).</p></caption><graphic xlink:href="EMS199524-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>A model of gepotidacin binding to DNA before forming the complex with <italic>S. aureus</italic> DNA-gyrase.</title><p><bold>(a)</bold> Gepotidacin and GSK299423 structures compared. LHS - left-hand side; RHS – right-hand side <bold>(b)</bold> A model of gepotidacin (yellow carbons) bound to DNA. The basic nitrogen has been modelled interacting (dotted red line) with a phosphate of the DNA backbone. <bold>(c)</bold> Gepotidacin bound to <italic>S.aureus</italic> DNA gyrase and DNA - the basic nitrogen interacts with one of the Asp 83s (dotted red line).</p></caption><graphic xlink:href="EMS199524-f006"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Twenty published P6<sub>1</sub> <italic>S. aureus</italic> DNA gyrase GyrB27–A56(GKdel) structures.</title><p>Four re-refined structures (*-v2-BA-x.pdb*) are highlighted (underlined structures are available with standard BA-x nomenclature from research tab at <ext-link ext-link-type="uri" xlink:href="https://profiles.cardiff.ac.uk/staff/baxb">https://profiles.cardiff.ac.uk/staff/baxb</ext-link> - click to download).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center">No. REF.</th><th valign="top" align="center">PDB code + Res in Å</th><th valign="top" align="center">Inhibitor Type</th><th valign="top" align="center">DNA sequence central six base-pairs<sup><xref ref-type="table-fn" rid="TFN1">1</xref></sup></th><th valign="top" align="center" colspan="6">Inhibitor pockets occupied<sup><xref ref-type="table-fn" rid="TFN2">2</xref></sup></th><th valign="top" align="center">Catal. Tyr 123<sup><xref ref-type="table-fn" rid="TFN3">3</xref></sup></th></tr><tr style="border-top: solid thin"><th valign="top" align="center"/><th valign="top" align="center"/><th valign="top" align="center"/><th valign="top" align="center"/><th valign="top" align="center"><bold>1</bold></th><th valign="top" align="center"><bold>1'</bold></th><th valign="top" align="center"><bold>2D</bold></th><th valign="top" align="center"><bold>2A</bold></th><th valign="top" align="center"><bold>3</bold></th><th valign="top" align="center"><bold>3'</bold></th><th valign="top" align="center"/></tr></thead><tbody><tr><td valign="top" align="center"><styled-content style="color:#FF0000">1 [<xref ref-type="bibr" rid="R11">11</xref>]</styled-content></td><td valign="top" align="center"><underline><styled-content style="color:#AE8297">2xcs-v2-BA-x.pdb</styled-content></underline><styled-content style="color:#FF0000">* 2.1Å</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">NBTI</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">5'GGGCCC 3'</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">Phe</styled-content></td></tr><tr><td valign="top" align="center"><bold>2 [<xref ref-type="bibr" rid="R27">27</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">4bul-BA-x.pdb</styled-content></underline> 2.6Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'TGTACC 3' 3'ACATGG 5'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>3 [<xref ref-type="bibr" rid="R29">29</xref>]</bold></td><td valign="top" align="center">4plb 2.69Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>4 [<xref ref-type="bibr" rid="R28">28</xref>]</bold></td><td valign="top" align="center">5bs3 2.65Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><styled-content style="color:#FF0000">5 [<xref ref-type="bibr" rid="R9">9</xref>]</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000"><bold><underline>5cdm-v2-BA-x.pdb* 2.5Å</underline></bold></styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">SPT</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">5'C-<sup>Y</sup>GGCCG 3'</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">Tyr<sup>P</sup></styled-content></td></tr><tr><td valign="top" align="center"><bold>6 [<xref ref-type="bibr" rid="R9">9</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#045BC6">5cdp-BA-x.pdb</styled-content></underline> 2.45Å</td><td valign="top" align="center">Etop.</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3'</bold></td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><styled-content style="color:#FF0000">7 [<xref ref-type="bibr" rid="R9">9</xref>]</styled-content></td><td valign="top" align="center"><bold><underline><styled-content style="color:#FF0000">5cdr-v2-BA-x.pdb</styled-content></underline><styled-content style="color:#FF0000">* 2.65Å</styled-content></bold></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">5'G-<sup>P</sup>GTACC 3'</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">Phe</styled-content></td></tr><tr><td valign="top" align="center"><styled-content style="color:#FF0000">8 [<xref ref-type="bibr" rid="R26">26</xref>]</styled-content></td><td valign="bottom" align="center"><underline><bold><styled-content style="color:#FF0000">5iwi-v2-BA-x.pdb</styled-content></bold></underline><styled-content style="color:#FF0000">* 1.98Å</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">NBTI</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">5'GGTAC A 3'</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">x</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">-</styled-content></td><td valign="top" align="center"><styled-content style="color:#FF0000">Phe</styled-content></td></tr><tr><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"><styled-content style="color:#FF0000">3'CCATG-T5'</styled-content></td><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/><td valign="top" align="center"/></tr><tr><td valign="top" align="center"><bold>9 [<xref ref-type="bibr" rid="R26">26</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#9E627F">5cdp-BA-x.pdb</styled-content></underline> 2.5Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5' GGTTCA 3'</bold><break/><bold>3' CCAAGT 5'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>10 [<xref ref-type="bibr" rid="R38">38</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">5npp-BA-x.pdb</styled-content></underline> 2.22Å</td><td valign="top" align="center">NBTI + thiop.</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">Tyr</td></tr><tr><td valign="top" align="center"><bold>11 [<xref ref-type="bibr" rid="R30">30</xref>]</bold></td><td valign="top" align="center">6fm4 2.7Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5' GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>12 [<xref ref-type="bibr" rid="R33">33</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">6fqs-BA-x.pdb</styled-content></underline> 3.11Å</td><td valign="top" align="center">IPY</td><td valign="top" align="center"><bold>5'C-<sup>Y</sup>GGCCG 3'</bold></td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Tyr<sup>P</sup></td></tr><tr><td valign="top" align="center"><bold>13 [<xref ref-type="bibr" rid="R6">6</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">6qtk-BA-x.pdb</styled-content></underline> 2.31Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>14 [<xref ref-type="bibr" rid="R39">39</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">6qx1-BA-x.pdb 2.65</styled-content></underline>Å</td><td valign="top" align="center">benzoi'</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>15 [<xref ref-type="bibr" rid="R40">40</xref>]</bold></td><td valign="top" align="center">6z1a 2.3Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>16 [<xref ref-type="bibr" rid="R31">31</xref>]</bold></td><td valign="top" align="center">7fvs 2.16Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>17 [<xref ref-type="bibr" rid="R31">31</xref>]</bold></td><td valign="top" align="center">7fvt 2.08Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>18 [<xref ref-type="bibr" rid="R32">32</xref>]</bold></td><td valign="top" align="center">7mvs 2.60Å</td><td valign="top" align="center">NBTI</td><td valign="top" align="center"><bold>5'GGGCCC 3'</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr><tr><td valign="top" align="center"><bold>19 [<xref ref-type="bibr" rid="R8">8</xref>]</bold></td><td valign="top" align="center"><underline><styled-content style="color:#022D62">8bp2-BA-x.pdb</styled-content></underline> 2.80Å</td><td valign="top" align="center">SPT</td><td valign="top" align="center"><bold>5'C-<sup>Y</sup>GGCCG 3'</bold></td><td valign="top" align="center">x</td><td valign="top" align="center">x</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Tyr<sup>P</sup></td></tr><tr><td valign="top" align="center"><styled-content style="color:#FF0000">20 t.p.</styled-content></td><td valign="top" align="center">9fz6-BA-x.pdb 2.58Å</td><td valign="top" align="center">-</td><td valign="top" align="center"><bold>5'G-<sup>P</sup>GTACC 3</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">-</td><td valign="top" align="center">Phe</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>1</label><p id="P43">Where only a single sequence is given the two sequences in the duplex are identical. Where the two strands have different DNA sequences the DNA has static disorder around the twofold axis.</p></fn><fn id="TFN2"><label>2</label><p id="P44">Pockets are defined in Bax et al., (2019 = [41]).</p></fn><fn id="TFN3"><label>3</label><p id="P45">In all structures determined to date the two catalytic residues are the same. If the catalytic Tyr is mutated to a Phe it cannot cleave the DNA. Residues Tyr<sup>P</sup> have cleaved the DNA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>pH versus Xtal contact Mn occupancy in four P6<sub>1</sub> <italic>S. aureus</italic> DNA gyrase structures.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center">PDB</th><th valign="top" align="center">Compound</th><th valign="top" align="center">Resol. (A)</th><th valign="top" align="center">Crystallization buffer pH</th><th valign="top" align="center">Mn C901 occupancy (Bfactor)</th><th valign="top" align="center">His C390 sidechain Bfactor</th></tr></thead><tbody><tr><td valign="top" align="center"><bold>2xcs-v2-BA-x.pdb</bold></td><td valign="top" align="center">GSK299423</td><td valign="top" align="center">2.10</td><td valign="top" align="center">6.5</td><td valign="top" align="center">0.65 (23.3)</td><td valign="top" align="center">23.7</td></tr><tr><td valign="top" align="center"><bold>5iwi-v2-BA-x.pdb</bold><xref ref-type="table-fn" rid="TFN4">*</xref></td><td valign="top" align="center">GSK945237</td><td valign="top" align="center">1.98</td><td valign="top" align="center">6.2</td><td valign="top" align="center">0.30 (35.8)</td><td valign="top" align="center">35.5</td></tr><tr><td valign="top" align="center"><bold>5cdm-v2-BA-x.pdb</bold></td><td valign="top" align="center">QPT-1</td><td valign="top" align="center">2.50</td><td valign="top" align="center">6.2</td><td valign="top" align="center">0.40 (55.2)</td><td valign="top" align="center">52.1<xref ref-type="table-fn" rid="TFN5">**</xref></td></tr><tr><td valign="top" align="center"><bold>5cdr-v2-BA-x.pdb</bold></td><td valign="top" align="center">-</td><td valign="top" align="center">2.65</td><td valign="top" align="center">6.2</td><td valign="top" align="center">0.30 (37.5)</td><td valign="top" align="center">45.8</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><label>*</label><p id="P46">5iwi-v2-BA-x.pdb contains two DNA strands with different sequences. The relatively high B-factor for the sidechain of His 390 in 5iwi-v2-BA-x.pdb is thought to be due to the two different strands of DNA in 5iwi.</p></fn><fn id="TFN5"><label>**</label><p id="P47">In 5cdm-v2-BA-x.pdb the side-chain of histidine 390 was modelled in two conformations, the B-factors given correspond to that with occupancy 0.4.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><title>Mn<sup>2+</sup> site occupancies compared to anomalous peak heights.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center">Mn Site</th><th valign="top" align="center">Occupancy</th><th valign="top" align="center">Peak Height (rmsd)</th></tr></thead><tbody><tr><td valign="top" align="center">B/5081</td><td valign="top" align="center">1.0</td><td valign="top" align="center">15.5</td></tr><tr><td valign="top" align="center">D/5081</td><td valign="top" align="center">1.0</td><td valign="top" align="center">15.1</td></tr><tr><td valign="top" align="center">E/1999</td><td valign="top" align="center">0.6</td><td valign="top" align="center">7.0</td></tr><tr><td valign="top" align="center">F/1999</td><td valign="top" align="center">0.5</td><td valign="top" align="center">4.3</td></tr><tr><td valign="top" align="center">C/901</td><td valign="top" align="center">0.2</td><td valign="top" align="center">4.0</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p id="P48">Peak height values were calculated with ANODE [<xref ref-type="bibr" rid="R57">57</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><title>A comparison of models proposed in literature for the first DNA-cleavage step of a type IIA topoisomerase.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center">Mechanism number and name</th><th valign="top" align="center">Problems with mechanism (current estimate of mechanism being broadly correct). Reference.</th></tr></thead><tbody><tr><td valign="top" align="center">(i) a two metal mechanism from 2010<break/><inline-graphic xlink:href="EMS199524-i001.jpg"/></td><td valign="top" align="center">No chemically sensible structure has yet been deposited in support of this mechanism. The X-ray data are consistent with a single moving metal mechanism (see figure 3). The topo1A lysine is also consistent with the single moving metal mechanism proposed in [<xref ref-type="bibr" rid="R49">49</xref>]. Some variation on this two- metal mechanism cannot be entirely excluded:<break/>(Low to very low)<break/>Schmidt et al., (2010) [<xref ref-type="bibr" rid="R42">42</xref>].</td></tr><tr><td valign="top" align="center">(ii) Single metal mechanism from 2019<break/><inline-graphic xlink:href="EMS199524-i002.jpg"/></td><td valign="top" align="center">The mechanism proposed does not detail any sensible chemistry. The mechanism seems to propose that the metal starts at the A-site and cleaves the DNA before moving to the B-site. Some variation on this mechanism cannot be excluded:<break/>(Low to very low)<break/>Bax et al., (2019)[<xref ref-type="bibr" rid="R41">41</xref>]</td></tr><tr><td valign="top" align="center">(iii) a single moving metal mechanism described in [<xref ref-type="bibr" rid="R49">49</xref>]<break/><inline-graphic xlink:href="EMS199524-i003.jpg"/></td><td valign="top" align="center">Only heavy atom (non-hydrogen atom) positions defined by experimental data. Mechanism suggests the red hydrogen atom from water 5093 will protonate the 3' oxygen on the scissile phosphate to cleave the DNA, after which the metaphosphate like intermediate will be accepted by the catalytic tyrosinate.<break/>(High to very high)<break/>(Nicholls et al., 2024) [<xref ref-type="bibr" rid="R49">49</xref>].</td></tr><tr><td valign="top" align="center">(iv) Some unthought of mechanism</td><td valign="top" align="center">(Low ?). No reference</td></tr></tbody></table></table-wrap></floats-group></article>